<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533611431985</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533611431985</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>HIV Medications</article-title>
<subtitle>An Update and Review of Metabolic Complications</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western"><surname>Hester</surname><given-names>E. Kelly</given-names></name>
<degrees>PharmD, BCPS, AAHIVE</degrees>
</contrib>
<aff id="aff1-0884533611431985">Auburn University Harrison School of Pharmacy, Auburn University, Auburn, Alabama</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0884533611431985">E. Kelly Hester, PharmD, BCPS, AAHIVE, Auburn University Harrison School of Pharmacy, Auburn University, 1321 Walker Building, Auburn, AL 36849; e-mail: <email xlink:type="simple">hesteek@auburn.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>1</issue>
  <issue-title>Micronutrients</issue-title>
<fpage>51</fpage>
<lpage>64</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>7</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>11</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>In the past 30 years, medical advances for those with human immunodeficiency virus (HIV) have reduced morbidity and mortality to extend life with highly active antiretroviral therapy (HAART) and with the continued development of new therapies. With this success, HIV is being managed chronically, but other health issues of an aging HIV-infected population have emerged. The challenges of treating HIV infection have shifted from AIDS-related mortality improvements to drug-induced disease from HAART, including cardiovascular disease, metabolic disorders, and bone health. Prolonged use of antiretroviral therapy maintaining immune restoration appears to represent additional, ongoing risk factors for the development of these metabolic complications. These drug-related problems continue to challenge patients and clinicians in the management of HIV disease, as well as ongoing research for drug development improvements to minimize these risks. These health risks imposed by HAART must be vigilantly monitored and aggressively addressed to improve the overall health of those treated for HIV infection.</p>
</abstract>
<kwd-group>
<kwd>HIV</kwd>
<kwd>cardiovascular diseases</kwd>
<kwd>bone density</kwd>
<kwd>lipodystrophy</kwd>
<kwd>HIV-associated lipodystrophy syndrome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>In the past 30 years, medical advances for those with human immunodeficiency virus (HIV) have reduced morbidity and mortality to extend life with the continued development of new therapies. With this success, HIV is being managed chronically, but other health issues of an aging HIV-infected population such as cardiovascular disease and osteoporosis have emerged. As patients are living longer, the prolonged use of antiretroviral therapy maintaining immune restoration appears to represent additional, ongoing risk factors for the development of these metabolic complications. These drug-related problems continue to challenge patients and clinicians in the management of HIV disease as well as clinical research for drug development improvements to minimize these risks. This article reviews the current HIV treatment guidelines and adverse effects related to current antiretroviral therapy.</p>
<sec id="section1-0884533611431985">
<title>HIV Infection and Targets of Drug Therapy</title>
<p>Following HIV exposure, the virus has a high affinity for CD4 receptors. The first step in the replication cycle is attachment and fusion of the virus to the CD4 cell.<sup><xref ref-type="bibr" rid="bibr1-0884533611431985">1</xref></sup> Once binding of HIV to the cell surface has occurred, the virus enters CD4 cells by the CD4 receptor and also by 1 of 2 chemokine receptors (CCR5 and CXCR4).<sup><xref ref-type="bibr" rid="bibr2-0884533611431985">2</xref></sup> HIV strains may use one or either of these coreceptors for cell entry. CCR5 antagonists and fusion inhibitors are currently targets of drug therapy. Following membrane fusion, the virus enters the CD4 cell, and the nucleic acid is uncoated. The next step in viral replication is transcription of RNA into DNA using the viral enzyme reverse transcriptase. Two of the major drug classes target this viral enzyme. Double-stranded DNA then integrates into the host cell DNA by the viral enzyme integrase. Drug therapy has been developed targeting this viral enzyme. Following further transcription and translation, a new virion is assembled and buds through the host cell bilipid layer. The final step in the HIV replication process is maturation. The viral enzyme protease cleaves long polyproteins into functional proteins necessary for complete maturation. Without this last step, the virus is rendered immature and noninfectious.</p>
</sec>
<sec id="section2-0884533611431985">
<title>Treatment Goals</title>
<p>In the United States, it is estimated that there are more than 1 million people living with HIV infection and 56,000 new cases of HIV infection diagnosed each year.<sup><xref ref-type="bibr" rid="bibr3-0884533611431985">3</xref></sup> The primary goal of therapy is to reduce morbidity and mortality. Attaining maximal suppression of viral replication to undetectable levels (&lt;20–50 copies/mL) is necessary to achieve this goal. Reduction in viral replication corresponds to fewer mutations and related antiretroviral resistance. Viral load is the primary indicator of response to therapy and clinical outcomes (disease progression).<sup><xref ref-type="bibr" rid="bibr4-0884533611431985">4</xref></sup> CD4 cell count is the major marker of immune function and the strongest predictor of disease progression and survival in patients with HIV infection.<sup><xref ref-type="bibr" rid="bibr5-0884533611431985">5</xref></sup> HIV has a high affinity for CD4 receptors, and viral replication within these cells results in CD4 cell depletion over time. Patients left untreated will become immunocompromised and at high risk of opportunistic infections such as <italic>Pneumocystis jiroveci</italic> pneumonia or malignancies such as non-Hodgkin’s lymphoma. Limiting viral replication allows restoration of CD4 counts and improved immune function. CD4 counts largely determine initiation of therapy as well as provide an indication of therapeutic response (approximately 50–150 cells/mm<sup>3</sup> per year). Immune restoration with antiretroviral therapy improves morbidity and mortality associated with HIV infection such as opportunistic infections. The majority of treatment-naive patients without resistance mutations can achieve viral load suppression in 4–8 weeks following initiation of highly active antiretroviral therapy (HAART). Those more treatment experienced typically can achieve suppression in 12–24 weeks following initiation of optimal therapy.</p>
</sec>
<sec id="section3-0884533611431985">
<title>When to Start HIV Treatment</title>
<p>The decision of when to initiate HAART must take into account the risks and benefits to the individual patient. Antiretroviral therapy is a lifelong commitment, so the patient’s readiness must be considered and assessed. The risks associated with HAART have improved with newer agents and include the potential for development of drug resistance with initiation of therapy and drug-related adverse effects. The benefits of antiretroviral therapy are clearly restoration of the immune system but also reduced mortality and morbidity that arise from end-organ damage from HIV infection. Historically, the CD4 count has been the marker in deciding when to initiate antiretroviral therapy based on evidence of improved survival and progression to AIDS. However, evidence has emerged over the past several years identifying additional benefits of initiating HAART. Untreated HIV infection generates and maintains a chronic inflammatory state that has been attributed to comorbidities such as cardiovascular disease, liver disease, kidney disease, neurocognitive decline, and malignancy regardless of CD4 count.<sup><xref ref-type="bibr" rid="bibr6-0884533611431985">6</xref></sup></p>
<p>Treatment guidelines currently recommend initiating HAART in all patients with a CD4 count &lt;500 cell/mm<sup>3</sup>.<sup><xref ref-type="bibr" rid="bibr5-0884533611431985">5</xref>,<xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup> Some HIV experts favor initiating HAART in patients with CD4 counts &gt;500 cells/mm<sup>3</sup>, whereas others consider treatment initiation optional at this point. The shift in treatment guidelines to earlier initiation antiretroviral therapy at higher CD4 counts is based on evidence of the harmful effects of ongoing HIV-associated inflammation and end-organ damage. Initiation of antiretroviral therapy is also indicated for the following patients regardless of baseline CD4 count: those with HIV-associated nephropathy (HIVAN), pregnant women, and patients coinfected with hepatitis B virus (HBV) who are appropriate for HBV treatment. Viral replication in untreated HIV infection results in renal injury (HIVAN).<sup><xref ref-type="bibr" rid="bibr8-0884533611431985">8</xref></sup> This is not commonly observed in treated patients, and in fact renal function stabilizes and improves with initiation of HAART and lowering of viral load in the kidney.<sup><xref ref-type="bibr" rid="bibr9-0884533611431985">9</xref></sup> All pregnant women are indicated for antiretroviral therapy regardless of the mother’s clinical status to reduce the risk of vertical transmission to the child. With therapy, the risk of mother-to-child transmission is &lt;2%.<sup><xref ref-type="bibr" rid="bibr10-0884533611431985">10</xref></sup> In patients with hepatitis B who are coinfected with HIV, they have been observed to more quickly experience hepatic failure and progression to end-stage liver disease, cirrhosis, and hepatocellular carcinoma.<sup><xref ref-type="bibr" rid="bibr11-0884533611431985">11</xref></sup> As a result, immune restoration with HIV virologic suppression is imperative. Last, antiretroviral treatment as a means of prevention of HIV-1 transmission has been investigated in recent years with public health implications. Evidence is clear that virologic suppression with HAART reduces sexual transmission of HIV. A recently published study observed a 96% reduced rate of HIV transmission to uninfected partners when HAART was initiated at higher CD4 cell counts (350–550) compared to those who deferred therapy.<sup><xref ref-type="bibr" rid="bibr12-0884533611431985">12</xref></sup> Although the original risks of initiation of therapy still remain, these results strengthen the argument for early initiation of antiretroviral therapy as a measure of prevention.</p>
</sec>
<sec id="section4-0884533611431985">
<title>Deferring Treatment</title>
<p>There are a number of circumstances in which deferring initiation or reinitiation of therapy may be prudent. Patients who currently have higher CD4 counts and are at higher risk of nonadherence may require additional time to prepare for the necessary commitment to sustained treatment adherence. Also, for patients who have temporary circumstances that may complicate or prohibit use of antiretroviral therapy such as surgical procedures or drug-drug interactions, therapy may be deferred.</p>
<p>A small percentage of HIV-infected patients (&lt;5%) are termed long-term nonprogressors or elite controllers.<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup> These patients are able to maintain high CD4 counts and possibly virologic suppression for many years. These patients would not likely benefit further from HAART until they begin to progress clinically. The decision to not treat at all would likely occur in medical conditions with a poor prognosis that HAART would not likely prolong survival or improve quality of life.</p>
</sec>
<sec id="section5-0884533611431985">
<title>What to Start</title>
<p>Numerous factors are taken into consideration when deciding on the initial HAART regimen in a treatment-naive patient. The regimen should be individualized with assessment of comorbid conditions such as renal or liver disease, cardiovascular disease, psychiatric illness, and substance abuse. Drug-specific considerations are also necessarily related to evidence of antiretroviral resistance, coreceptor tropism results, adverse effects, baseline CD4 count, pregnancy or childbearing potential, drug-drug interactions, likelihood of adherence, and overall convenience.<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup> Coreceptor tropism refers to the type of virus (CCR5-tropic, CXCR4-tropic, or a mixture of both “dual/mixed-tropic”) a patient is infected with. This often changes over time and becomes necessary information when ascertaining the utility of CCR5 inhibitors for a given patient.</p>
<p>Currently, there are more than 20 antiretroviral agents available for use in combination therapy to treat HIV infection (<xref ref-type="table" rid="table1-0884533611431985">Table 1</xref>). The available drug classes include nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), entry inhibitors (fusion inhibitors and CCR5 antagonists), and integrase inhibitors (INSTIs). Of these, there are 4 preferred regimens recommended by the Department of Health and Human Services HIV guidelines as initial treatment for nonpregnant treatment-naive HIV-infected patients.<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup> All HAART regimens contain 3 active antiretroviral medications. Preferred regimens have demonstrated optimal, durable, and comparable efficacy in clinical trials and have the advantages of good tolerability, minimal toxicities, and greater convenience compared to other class agents. The preferred NNRTI- and PI-based regimens are dosed once daily for convenience and are generally well tolerated. The preferred dual-NRTI backbone is tenofovir and emtricitabine. This backbone is combined with either the preferred NNRTI efavirenz or the preferred PI atazanavir or darunavir both boosted with ritonavir. Small doses of ritonavir (100–200 mg) added to other protease inhibitors achieve higher concentrations and longer half-lives of the paired PI, which delays the development of PI resistance. The fourth preferred regimen clinicians can select is an NNRTI/PI-sparing regimen using raltegravir from a newer class of agents (integrase inhibitors) with the tenofovir/emtricitabine backbone. Several alternative regimens are also effective and may be used but have disadvantages relative to the preferred regimens. However, for the individual patient, one of the alternative regimens may be more appropriate.</p>
<table-wrap id="table1-0884533611431985" position="float">
<label>Table 1.</label>
<caption>
<p>Antiretroviral Therapy, Dosage, and Administration<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref>,<xref ref-type="bibr" rid="bibr13-0884533611431985">13</xref></sup></p>
</caption>
<graphic alt-version="no" alternate-form-of="table1-0884533611431985" position="float" xlink:href="10.1177_0884533611431985-table1.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Food and Drug Administration Approved</th>
<th align="center" colspan="1" rowspan="1">Name</th>
<th align="center" colspan="1" rowspan="1">Dosing</th>
<th align="center" colspan="1" rowspan="1">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4" rowspan="1">Nucleoside reverse transcriptase inhibitors (NRTIs)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1987</td>
<td colspan="1" rowspan="1">Zidovudine (Retrovir –GlaxoSmithKline, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">300 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1991</td>
<td colspan="1" rowspan="1">Didanosine (Videx EC - Bristol-Myers Squibb, Princeton, NJ</td>
<td colspan="1" rowspan="1">Body weight &gt;60 kg: 200 mg twice daily or 400 mg once daily<break/>Body weight &lt;60 kg: 250 mg once daily</td>
<td colspan="1" rowspan="1">Enteric-coated capsules. Take 30 minutes before meals or two hours after a meal.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1994</td>
<td colspan="1" rowspan="1">Stavudine (Zerit - Bristol-Myers Squibb, Princeton, NJ</td>
<td colspan="1" rowspan="1">Body weight &gt;60 kg: 40 mg twice daily<break/>Body weight &lt;60 kg: 30 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1995</td>
<td colspan="1" rowspan="1">Lamivudine (Epivir – GlaxoSmithKline, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">300 mg once daily or 150 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1997</td>
<td colspan="1" rowspan="1">Lamivudine/zidovudine (Combivir – GlaxoSmithKline, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">150/300 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1998</td>
<td colspan="1" rowspan="1">Abacavir(Ziagen - (GlaxoSmithKline, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">300 mg twice daily or 600 mg once daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2000</td>
<td colspan="1" rowspan="1">Lamivudine/zidovudine/abacavir(Trizivir – GlaxoSmithKline, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">150/300/300 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2001</td>
<td colspan="1" rowspan="1">Tenofovir(Viread - Gilead Sciences, Inc., Foster City, CA )</td>
<td colspan="1" rowspan="1">300 mg once daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2003</td>
<td colspan="1" rowspan="1">Emtricitabine(Emtriva - Gilead Sciences, Inc., Foster City, CA)</td>
<td colspan="1" rowspan="1">200 mg once daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2004</td>
<td colspan="1" rowspan="1">Lamivudine/abacavir(Epzicom – GlaxoSmithKline, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">300/600 mg once daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2004</td>
<td colspan="1" rowspan="1">Emtricitabine/tenofovir(Truvada - Gilead Sciences, Inc., Foster City, CA)</td>
<td colspan="1" rowspan="1">200/300 mg once daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Nonnucleoside reverse transcriptase inhibitors (NNRTIs)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1996</td>
<td colspan="1" rowspan="1">Nevirapine(Viramune - Boehringer Ingelheim Pharmaceuticals, Inc.Ridgefield, CT)</td>
<td colspan="1" rowspan="1">200 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1997</td>
<td colspan="1" rowspan="1">Delavirdine(Rescriptor - Pharmacia and Upjohn Company, Division of Pfizer Inc., New York, NY)</td>
<td colspan="1" rowspan="1">400 mg 3 times a day</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1998</td>
<td colspan="1" rowspan="1">Efavirenz(Sustiva - Bristol-Myers Squibb,Princeton, NJ)</td>
<td colspan="1" rowspan="1">600 mg once daily at bedtime</td>
<td colspan="1" rowspan="1">Take on an empty stomach to minimize side effects.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2008</td>
<td colspan="1" rowspan="1">Etravirine( Intelence - Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, L.P., Raritan NJ)</td>
<td colspan="1" rowspan="1">200 mg twice daily</td>
<td colspan="1" rowspan="1">Take following a meal.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2011</td>
<td colspan="1" rowspan="1">Rilpivirine(Edurant - Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, L.P., Raritan NJ)</td>
<td colspan="1" rowspan="1">25 mg once daily</td>
<td colspan="1" rowspan="1">Take following a full meal.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Protease inhibitors (PIs)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1995</td>
<td colspan="1" rowspan="1">Saquinavir(Invirase - Genentech USA, Inc. A member of the Roche group,San Francisco, CA)</td>
<td colspan="1" rowspan="1">1000 mg twice daily</td>
<td colspan="1" rowspan="1"><sup><xref ref-type="table-fn" rid="table-fn2-0884533611431985">a</xref></sup>Must be given with ritonavir. Take with food.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1996</td>
<td colspan="1" rowspan="1">Indinavir (Crixivan - Merck and Co., Inc., Whitehouse Station, NJ)</td>
<td colspan="1" rowspan="1">800 mg every 8 hours</td>
<td colspan="1" rowspan="1">Take one hour before meals or two hours after a meal; if co-administered with ritonavir may be taken without regard to food.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1996</td>
<td colspan="1" rowspan="1">Ritonavir(Norvir - Abbott Laboratories,North Chicago, IL)</td>
<td colspan="1" rowspan="1">used 100-200mg once or twice daily with other protease inhibitors</td>
<td colspan="1" rowspan="1">Take with food.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 1997</td>
<td colspan="1" rowspan="1">Nelfinavir(Viracept - Agouron Pharmaceuticals, Inc.,La Jolla, CA)</td>
<td colspan="1" rowspan="1">1250 mg twice daily</td>
<td colspan="1" rowspan="1">Take with food.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2000</td>
<td colspan="1" rowspan="1">Lopinavir/ritonavir(Kaletra - Abbott Laboratories,North Chicago, IL)</td>
<td colspan="1" rowspan="1">400/100 mg twice daily</td>
<td colspan="1" rowspan="1">Take tablets without regard to meals. Take solution with food.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2003</td>
<td colspan="1" rowspan="1">Fosamprenavir(Lexiva – GlaxoSmithKline, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">1400 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2003</td>
<td colspan="1" rowspan="1">Atazanavir(Reyataz - Bristol-Myers Squibb,Princeton, NJ)</td>
<td colspan="1" rowspan="1">400 mg once daily</td>
<td colspan="1" rowspan="1">Take with food.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2005</td>
<td colspan="1" rowspan="1">Tipranavir(Aptivus - Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT)</td>
<td colspan="1" rowspan="1">500 mg twice daily</td>
<td colspan="1" rowspan="1">must be given with ritonavir<sup><xref ref-type="table-fn" rid="table-fn2-0884533611431985">a</xref></sup> Take with food.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2006</td>
<td colspan="1" rowspan="1">Darunavir(Prezista - Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, L.P., Raritan NJ)</td>
<td colspan="1" rowspan="1">600 mg twice daily or 800 mg once daily</td>
<td colspan="1" rowspan="1">must be given with ritonavir<sup><xref ref-type="table-fn" rid="table-fn2-0884533611431985">a</xref></sup> Take with food.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">HIV integrase strand transfer inhibitors</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2007</td>
<td colspan="1" rowspan="1">Raltegravir(Isentress - Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.,Whitehouse Station, NJ)</td>
<td colspan="1" rowspan="1">400 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Fusion inhibitors</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2003</td>
<td colspan="1" rowspan="1">Enfuvirtide(Fuzeon - (Genentech USA, Inc. A member of the Roche group,San Francisco, CA)</td>
<td colspan="1" rowspan="1">90 mcg SQ twice daily</td>
<td colspan="1" rowspan="1">Rotate injection sites.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Entry inhibitors—CCR5 coreceptor antagonists<sup><xref ref-type="table-fn" rid="table-fn3-0884533611431985">b</xref></sup></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2007</td>
<td colspan="1" rowspan="1">Maraviroc(Selzentry - ViiV Healthcare, Research Triangle Park, NC)</td>
<td colspan="1" rowspan="1">300 mg twice daily</td>
<td colspan="1" rowspan="1">Take without regard to meals.</td>
</tr>
<tr>
<td colspan="4" rowspan="1">Multiclass combination products</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2006</td>
<td colspan="1" rowspan="1">Emtricitabine/tenofovir/efavirenz(Atripla - Bristol-Myers Squibb,Princeton, NJ; Gilead Sciences, Inc., Foster City, CA)</td>
<td colspan="1" rowspan="1">200/300/600 mg once daily at bedtime</td>
<td colspan="1" rowspan="1">Take on an empty stomach to minimize side effects.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> 2011</td>
<td colspan="1" rowspan="1">Emtricitabine/tenofovir/rilpivirine(Complera - Gilead Sciences, Inc., Foster City, CA)</td>
<td colspan="1" rowspan="1">200/300/25 mg once daily</td>
<td colspan="1" rowspan="1">Take with a full meal.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533611431985">
<p>Adapted from Department of Health and Human Services guidelines.<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup></p>
</fn>
<fn id="table-fn2-0884533611431985">
<label>a</label>
<p>Low- dose ritonavir dosing varies with paired PI.</p>
</fn>
<fn id="table-fn3-0884533611431985">
<label>b</label>
<p>Dosing varies with concomitant antiretroviral therapy.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In selecting an NNRTI- or a PI-based regimen, there are several advantages and disadvantages to consider. Compared to PIs, the primary disadvantages in using NNRTIs are that they have a low genetic barrier to resistance with only a single-point mutation necessary to confer high-level resistance and cross-resistance to others in the class as well as a high prevalence of baseline resistance to this class (8%).<sup><xref ref-type="bibr" rid="bibr14-0884533611431985">14</xref></sup> The PIs, in contrast, require multiple mutations to confer high-level resistance, especially with ritonavir-boosted regimens. However, the disadvantages of PIs include more gastrointestinal symptoms, although the newer agents such as darunavir and atazanavir are much more tolerable than the earlier PIs (nelfinavir and indinavir). Additional adverse effects include metabolic complications, which are further elaborated on below. The PIs have traditionally been associated with a higher pill burden, but this has also improved with the newer agents (<xref ref-type="table" rid="table1-0884533611431985">Table 1</xref>). Efforts have been made to research the pharmacokinetics of once-daily dosing of PIs with good success in treatment-naive patients. The PIs selected as preferred therapy have minimal pill burden. Both NNRTIs and PIs are metabolized by the CYP3A4 enzyme system and affect other medications that are substrates metabolized through this system, and therefore drug-drug interactions must be evaluated with concomitant prescription medications.</p>
<p>Patient-specific considerations with initial therapy include that efavirenz is not recommended for women who are pregnant or who may become pregnant due to inconsistent contraception related to teratogenicity. Also, there is a low incidence (0.2%–2.4%) of central nervous system (CNS) psychiatric side effects (ie, severe depression, suicidal ideation, aggressive or paranoid behavior), and this should be considered in those with a history of psychiatric illness.<sup><xref ref-type="bibr" rid="bibr15-0884533611431985">15</xref></sup> Protease inhibitors contribute to the development of metabolic complications, including insulin resistance, dyslipidemia, and cardiovascular disease. It may be reasonable in those patients with a history of diabetes or at high risk for cardiovascular disease based on risk factors to select a PI-sparing regimen initially.</p>
</sec>
<sec id="section6-0884533611431985">
<title>Newest Additions of Antiretroviral Therapy</title>
<p>In 2007, raltegravir, a new class of antiretroviral therapy (integrase strand transfer inhibitors), was marketed. The efficacy of this agent has produced comparable and durable results to efavirenz.<sup><xref ref-type="bibr" rid="bibr16-0884533611431985">16</xref></sup> This, coupled with excellent tolerability and minimal drug-drug interactions, led to the decision as a first-line option in treatment-naive patients. Raltegravir has great utility as a new option for treatment-experienced patients who have multidrug resistance with other drug classes. That same year, maraviroc was also marketed, which is the first antiretroviral in the new drug class of CCR5 antagonists. Two other CCR5 inhibitors (aplaviroc and vicriviroc) were discontinued during clinical trials due to hepatotoxicity and viral breakthrough, respectively. This medication represents an acceptable treatment option in combination therapy early in HIV disease in patients who have exclusively CCR5-tropic virus. In these patients, the virus uses only the CCR5 coreceptor for viral entry into the host cells. A tropism assay must be evaluated prior to use of the medication to verify this. If a patient has CXCR4-tropic or dual/mixed-tropic virus, maraviroc will not be efficacious. Maraviroc also has good tolerability, but it is metabolized by CYP3A4, and drug-drug interactions with concomitant antiretroviral therapy must be considered. In 2008, the first second-generation NNRTI, etravirine, became available, which has had great utility and provided a much-needed treatment option for those patients with a history of NNRTI class resistance. In May 2011, a new once-daily NNRTI, rilpivirine, was marketed following 2 clinical studies demonstrating noninferior efficacy against the preferred NNRTI, efavirenz, in treatment-naive patients.<sup><xref ref-type="bibr" rid="bibr17-0884533611431985">17</xref>,<xref ref-type="bibr" rid="bibr18-0884533611431985">18</xref></sup> Rilpivirine was better tolerated than efavirenz in both studies, but the virological failure rate was slightly higher than efavirenz, which is being further investigated. It is notable that a high-calorie meal (&gt;500 calories) is necessary for adequate absorption.<sup><xref ref-type="bibr" rid="bibr19-0884533611431985">19</xref></sup> Rilpivirine, however, will likely be a beneficial NNRTI treatment option in the management of HIV infection. Each of the newer antiretroviral treatment options must be coadministered with other antiretrovirals as part of the HAART regimen.</p>
</sec>
<sec id="section7-0884533611431985">
<title>Monitoring Recommendations</title>
<p>The current HIV guidelines recommend that in addition to viral load and CD4 count, all patients entering care should also have fasting blood glucose; serum lipid panels; complete blood count; chemistry profile, including serum creatinine; transaminase levels; urinalysis; and HIV genotypic resistance testing evaluated at baseline.<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup> These results are necessary to guide the selection of initial therapy. Virologic and immunologic response to therapy should be monitored every 3 months. HIV drug resistance testing is recommended upon entry to care in light of recent evidence that 3%–5% of new infections have resistance to more than one drug class and 6%–16% to at least one antiretroviral therapy medication.<sup><xref ref-type="bibr" rid="bibr20-0884533611431985">20</xref>,<xref ref-type="bibr" rid="bibr21-0884533611431985">21</xref></sup> When virologic failure is evident on antiretroviral therapy, resistance testing is indicated to evaluate development of resistance to the current regimen.</p>
</sec>
<sec id="section8-0884533611431985">
<title>Adverse Effects</title>
<p>Most initial antiretroviral therapy will be associated with mild, transient gastrointestinal symptoms that improve with continued use of the medications. Occasionally, patients will develop rashes, liver function changes (transaminases, bilirubin), or renal dysfunction that will necessitate a change in therapy. A large number of patients will experience metabolic complications with therapy, including dyslipidemia, insulin resistance, and possibly fat redistribution. This is discussed in greater detail below.</p>
</sec>
<sec id="section9-0884533611431985">
<title>Drug Interactions</title>
<p>Antiretroviral medications in each drug class have important drug-drug interactions that must be considered (<xref ref-type="table" rid="table2-0884533611431985">Table 2</xref>). Food-drug interactions are important counseling points to ensure adequate absorption of each agent or avoidance of undesired side effects from increased rates of absorption (efavirenz). PIs, NNRTIs, and maraviroc are metabolized by CYP3A4, but PIs and NNRTIs also can inhibit or induce the metabolism of other medications that are substrates of this pathway. Concomitant medications must be reviewed to reduce the potential for virologic failure or, conversely, therapeutic failure or supratherapeutic concentrations and associated adverse effects of the paired medication. Lastly, over-the-counter (OTC) medication use (ie, proton pump inhibitors) and herbal use (ie, St John’s wort) must be identified prior to HAART use and patient counseling offered to avoid drug interactions that could result in virologic failure. The bioavailability of some antiretrovirals is reduced with increased gastric pH, and the induced metabolism of antiretrovirals by St John’s wort has been established.</p>
<table-wrap id="table2-0884533611431985" position="float">
<label>Table 2.</label>
<caption>
<p>Drug Interactions With Antiretroviral Therapy<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref>,<xref ref-type="bibr" rid="bibr19-0884533611431985">19</xref>,<xref ref-type="bibr" rid="bibr22-0884533611431985">22</xref></sup></p>
</caption>
<graphic alt-version="no" alternate-form-of="table2-0884533611431985" position="float" xlink:href="10.1177_0884533611431985-table2.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Clinical Concern</th>
<th align="center" colspan="1" rowspan="1">Mechanism</th>
<th align="center" colspan="1" rowspan="1">Antiretroviral Therapy</th>
<th align="center" colspan="1" rowspan="1">Concomitant Medication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Reduced concentrations of antiretroviral therapy</td>
<td colspan="1" rowspan="1">↑ gastric pH</td>
<td colspan="1" rowspan="1">Atazanavir<break/>
Fosamprenavir<break/>
Tipranavir<break/>
Rilpivirine</td>
<td colspan="1" rowspan="1">Antacids<break/>
H2 antagonists<break/>
Proton-pump inhibitors</td>
</tr>
<tr>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">Induction of CYP3A4 metabolism</td>
<td colspan="1" rowspan="1">Protease inhibitors<break/>
Nonnucleoside reverse transcriptase inhibitors</td>
<td colspan="1" rowspan="1">Anticonvulsant therapy (phenytoin, lamotrigine, phenobarbital)<break/>
Anti-mycobacterials (rifampin,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> rifapentine<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>)<break/>
Herbal therapy (St John’s wort<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Increased concentrations of antiretroviral therapy</td>
<td colspan="1" rowspan="1">Unknown</td>
<td colspan="1" rowspan="1">Saquinavir</td>
<td colspan="1" rowspan="1">Omeprazole</td>
</tr>
<tr>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">Inhibition of CYP3A4 metabolism</td>
<td colspan="1" rowspan="1">Protease inhibitors</td>
<td colspan="1" rowspan="1">Valproic acid<break/>
Anti-infective therapy (posaconazole)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reduced concentrations of concomitant therapy</td>
<td colspan="1" rowspan="1">Unknown<break/>
Induction of CYP3A4 metabolism</td>
<td colspan="1" rowspan="1">Darunavir, tipranavir, fosamprenavir, lopinavir/ritonavir<break/>
Efavirenz, ritonavir</td>
<td colspan="1" rowspan="1">Antidepressant therapy (bupropion, paroxetine, sertraline)<break/>
Cholesterol-lowering therapy (atorvastatin)<break/>
Hormonal contraceptive therapy (ethinyl estradiol, norethindrone)<break/>
Anti-infective therapy (voriconazole with ritonavir, clarithromycin with efavirenz)<break/>
Opioid dependence treatment (methadone)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Increased concentrations of concomitant therapy</td>
<td colspan="1" rowspan="1">Inhibition of CYP3A4 metabolism or transport mechanisms</td>
<td colspan="1" rowspan="1">Protease inhibitors</td>
<td colspan="1" rowspan="1">Cholesterol-lowering agents (simvastatin,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> lovastatin,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> atorvastatin, rosuvastatin, pravastatin, pitavastatin<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>)<break/>
Anti-infectives (itraconazole, voriconazole, clarithromycin)<break/>
Sedative hypnotics (midazolam,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> triazolam,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> alprazolam)<break/>
Opioid dependence treatment (buprenorphine)<break/>
Cardiovascular agents (amiodarone,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> flecainide,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> propafenone,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> quinidine,<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup> calcium channel blockers, bosentan<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>)<break/>
Ergot derivatives<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>
<break/>
Cisapride<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>
<break/>
Neuroleptics (pimozide<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>)<break/>
Inhaled corticosteroids (fluticasone<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>)<break/>
Inhaled β-agonists (salmeterol<sup><xref ref-type="table-fn" rid="table-fn5-0884533611431985">a</xref></sup>)<break/>
Erectile dysfunction agents (sildenafil, tadalafil, vardenafil)<break/>
Colchicine</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0884533611431985">
<p>Adapted from Department of Health and Human Services guidelines.<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup>
</p>
</fn>
<fn id="table-fn5-0884533611431985">
<label>a</label>
<p>Contraindicated with antiretroviral therapy.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0884533611431985">
<title>Cardiovascular Health</title>
<p>Although the outcomes of HAART represent a milestone in the medical management of HIV infection, the long-term complications associated with this therapy must now be addressed. The current shift in the clinical management has been to reduce the risk of cardiovascular disease imposed by the life-saving medications. Drug-induced dyslipidemia, insulin resistance, and lipodystrophy are described below.</p>
<sec id="section11-0884533611431985">
<title>Dyslipidemia</title>
<p>Lipid abnormalities in HIV-infected patients are not uncommon and have been reported in 26% of treatment-naive patients, increasing to 74% in patients treated with PIs.<sup><xref ref-type="bibr" rid="bibr23-0884533611431985">23</xref></sup> It is believed that chronic HIV infection contributes to the atherosclerotic process. Research suggests that cytokine (ie, tumor necrosis factor [TNF], interleukin-1, and interleukin-6) production relates to an ongoing inflammatory process.<sup><xref ref-type="bibr" rid="bibr24-0884533611431985">24</xref></sup> The pathogenesis of dyslipidemia observed in patients with HIV infection may develop in multiple ways (in the absence of other risk factors such as diabetes or family history). In vitro studies of HIV-infected cells have demonstrated that the virus itself has a direct impact on the adipose tissue, resulting in augmented fatty acid synthesis and low-density lipoprotein (LDL) lipoproteins, altered lipid metabolism and transport mechanisms, increased triglyceride production, and lipid oxidation.<sup><xref ref-type="bibr" rid="bibr25-0884533611431985">25</xref></sup> Active HIV replication and disease progression can result in declines in serum levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, and LDL cholesterol. Lipid changes related to PI therapy appear to be multifactorial. Proposed mechanisms include PI-induced hepatic triglyceride synthesis or inhibition of triglyceride clearance, inhibition of adipocyte fat metabolism, or disruption of retinoid signaling pathways.<sup><xref ref-type="bibr" rid="bibr26-0884533611431985">26</xref>-<xref ref-type="bibr" rid="bibr28-0884533611431985">28</xref></sup> HIV infection of smooth muscle also appears to contribute to endothelial dysfunction.<sup><xref ref-type="bibr" rid="bibr29-0884533611431985">29</xref>,<xref ref-type="bibr" rid="bibr30-0884533611431985">30</xref></sup></p>
<p>Before the advent of HAART, lipid abnormalities were described in HIV patients.<sup><xref ref-type="bibr" rid="bibr31-0884533611431985">31</xref></sup> This clinical presentation in asymptomatic patients was an isolated hypertriglyceridemia in many cases accompanied by a reduction in plasma concentrations of HDL cholesterol and low total cholesterol, especially with disease progression to AIDS. When PIs became available, the dyslipidemia presentation changed. Increases in total cholesterol, LDL cholesterol, and triglycerides with decreases in HDL and apolipoproteins were observed.<sup><xref ref-type="bibr" rid="bibr32-0884533611431985">32</xref></sup> Although patients are always treated with combination antiretroviral therapy, some agents produce greater lipid changes than others. Protease inhibitors and NNRTIs have demonstrated variable effects on the lipid profile. Of the PIs, ritonavir has the greatest association with hyperlipidemia, with up to a 7.2-fold risk of hypertriglyceridemia relative to other PIs.<sup><xref ref-type="bibr" rid="bibr33-0884533611431985">33</xref></sup> Conversely, elevations in HDL have been observed in patients taking the NNRTIs efavirenz and nevirapine.<sup><xref ref-type="bibr" rid="bibr34-0884533611431985">34</xref>,<xref ref-type="bibr" rid="bibr35-0884533611431985">35</xref></sup> The effects of this class on triglycerides have varied, with the individual agents ranging from worsening to improving with switch strategies. In general, newer antiretroviral therapies have had a more favorable lipid profile.</p>
<p>Investigators have reported a 26% increased risk of myocardial infarction (MI) with each year of continued use of HAART.<sup><xref ref-type="bibr" rid="bibr36-0884533611431985">36</xref></sup> In addition, it has been estimated that HIV-infected patients are at a 1.5- to 2.0-fold higher risk of cardiovascular events than non-HIV-infected individuals.<sup><xref ref-type="bibr" rid="bibr37-0884533611431985">37</xref></sup> Higher risk in HIV-infected patients may be in part attributed to higher tobacco and substance abuse (cocaine and alcohol).</p>
<p>Studies have determined that although HAART can contribute to cardiovascular risk, it is a greater risk not to treat the patient.<sup><xref ref-type="bibr" rid="bibr38-0884533611431985">38</xref>,<xref ref-type="bibr" rid="bibr39-0884533611431985">39</xref></sup> Research investigating the risks and benefits of intermittent HAART observed a higher rate of CVD and greater inflammatory markers associated with interruptions in therapy. Antiretroviral therapy reduces the HIV-related inflammation contributing to cardiovascular disease. Treatment guidelines for the management of dyslipidemia in patients with HIV infection have been published.<sup><xref ref-type="bibr" rid="bibr40-0884533611431985">40</xref></sup> Patients should be evaluated and the treatment approach made similar to those without HIV infection. The lipid abnormality with the greatest concern should be addressed with pharmacotherapy. At this point, LDL goals in those with HIV infection are determined in accordance with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines for non-HIV-infected individuals.<sup><xref ref-type="bibr" rid="bibr41-0884533611431985">41</xref></sup> In patients on PI therapy, drug-drug interactions with statin therapy must be considered and appropriate selections chosen to avoid potential myopathy and rhabdomyolysis. Fibrates are effective in patients with isolated hypertriglyceridemia or in combination with statins in mixed dyslipidemia,<sup><xref ref-type="bibr" rid="bibr42-0884533611431985">42</xref></sup> although niacin has demonstrated safety and efficacy in HIV-infected patients with hypertriglyceridemia and low HDL.<sup><xref ref-type="bibr" rid="bibr43-0884533611431985">43</xref></sup> However, in light of new evidence demonstrating a lack of efficacy in reducing cardiovascular events in HIV-negative patients on statin therapy with a history of cardiovascular disease, it should be used with caution.<sup><xref ref-type="bibr" rid="bibr44-0884533611431985">44</xref></sup></p>
<p>Ezetimibe has been studied for treatment in HIV-infected patients and found to be safe and effective in lowering LDL.<sup><xref ref-type="bibr" rid="bibr45-0884533611431985">45</xref></sup> Another approach to the management of dyslipidemia has been switching antiretroviral therapy to agents with less metabolic impact (<xref ref-type="table" rid="table3-0884533611431985">Table 3</xref>). This has proven beneficial in most circumstances without loss of virologic suppression. The newer antiretroviral therapy to be developed and marketed (integrase inhibitors, second-generation NNRTIs) appears to have a more favorable lipid profile (raltegravir and etravirine).</p>
<table-wrap id="table3-0884533611431985" position="float">
<label>Table 3.</label>
<caption>
<p>Metabolic Complications With Antiretroviral Therapy<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref>,<xref ref-type="bibr" rid="bibr40-0884533611431985">40</xref>,<xref ref-type="bibr" rid="bibr55-0884533611431985">55</xref>,<xref ref-type="bibr" rid="bibr96-0884533611431985">96</xref></sup></p>
</caption>
<graphic alt-version="no" alternate-form-of="table3-0884533611431985" position="float" xlink:href="10.1177_0884533611431985-table3.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Complication</th>
<th align="center" colspan="1" rowspan="1">Clinical Presentation</th>
<th align="center" colspan="1" rowspan="1">Associated Antiretroviral Therapy</th>
<th align="center" colspan="1" rowspan="1">Management</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Dyslipidemia</td>
<td colspan="1" rowspan="1">↑ triglycerides<break/>
↑ LDL</td>
<td colspan="1" rowspan="1">Stavudine<break/>
Zidovudine<break/>
Abacavir<break/>
Efavirenz<break/>
Protease inhibitors</td>
<td colspan="1" rowspan="1">Lifestyle modifications<break/>
Lipid-lowering therapy (fibrates, HMG-CoA reductase inhibitors, fish oil, etc)<break/>
ARV substitutions, including different protease inhibitors</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Insulin resistance and diabetes mellitus</td>
<td colspan="1" rowspan="1">Impaired fasting glucose</td>
<td colspan="1" rowspan="1">Stavudine<break/>
Didanosine<break/>
Zidovudine<break/>
Indinavir<break/>
Lopinavir/ritonavir</td>
<td colspan="1" rowspan="1">ARV substitutions, including different protease inhibitors<break/>
Progression to diabetes: metformin or pioglitazone</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Lipodystrophy</td>
<td colspan="1" rowspan="1">Increased abdominal fat tissue (lipohypertrophy) and peripheral fat wasting in limbs and facial tissue (lipoatrophy)</td>
<td colspan="1" rowspan="1">Stavudine<break/>
Zidovudine<break/>
Efavirenz<break/>
Protease inhibitors</td>
<td colspan="1" rowspan="1">Lipoatrophy:<break/>
 ARV substitutions<break/>
 Facial fillers (poly-L-lactic acid)<break/>
Lipohypertrophy:<break/>
 Lifestyle modifications<break/>
 Growth hormone–releasing hormone (tesamorelin)<break/>
Surgery (liposuction)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vitamin D deficiency</td>
<td colspan="1" rowspan="1">1,25(OH)<sub>2</sub>D &lt;30 ng/mL</td>
<td colspan="1" rowspan="1">Protease inhibitors<break/>
Efavirenz</td>
<td colspan="1" rowspan="1">Treatment: ergocalciferol 50,000 IU weekly for 8–12 weeks<break/>
Maintenance: ergocalciferol 1500–2000 IU daily</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0884533611431985">
<p>ARV, antiretroviral; LDL, low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0884533611431985">
<title>Insulin Resistance and Diabetes Mellitus</title>
<p>Prior to the HAART era, glucose abnormalities in HIV patients developed on medications for wasting such as megesterol acetate, human growth hormone, and androgenic steroids.<sup><xref ref-type="bibr" rid="bibr46-0884533611431985">46</xref></sup> Prospective studies have demonstrated that following initiation of HAART, insulin resistance increases with continued use over time.<sup><xref ref-type="bibr" rid="bibr47-0884533611431985">47</xref>,<xref ref-type="bibr" rid="bibr48-0884533611431985">48</xref></sup> The prevalence of insulin resistance has been estimated as 13% in treatment-naive patients following 1 year of HAART<sup><xref ref-type="bibr" rid="bibr49-0884533611431985">49</xref></sup> and as 7%–14% in HIV-infected patients diagnosed with diabetes following HAART initiation.<sup><xref ref-type="bibr" rid="bibr50-0884533611431985">50</xref>,<xref ref-type="bibr" rid="bibr51-0884533611431985">51</xref></sup></p>
<p>At least 2 primary potential mechanisms contribute to glucose abnormalities in patients taking antiretroviral therapy. First, peripheral glucose uptake is decreased by direct inhibition of the glucose transporter GLUT-4 by protease inhibitors.<sup><xref ref-type="bibr" rid="bibr52-0884533611431985">52</xref></sup> Second, NRTIs have the potential to cause mitochondrial toxicity in the skeletal muscle and subcutaneous adipose tissues that has been linked to lipoatrophy.<sup><xref ref-type="bibr" rid="bibr53-0884533611431985">53</xref>,<xref ref-type="bibr" rid="bibr54-0884533611431985">54</xref></sup> Also, patients taking the NRTIs zidovudine and stavudine have had an increased prevalence of diabetes.<sup><xref ref-type="bibr" rid="bibr51-0884533611431985">51</xref>,<xref ref-type="bibr" rid="bibr55-0884533611431985">55</xref></sup> As a result, it is believed that antiretroviral therapy may indirectly affect insulin sensitivity in the tissues greatly regulating glucose metabolism.</p>
<p>Drug-induced insulin resistance is not a class effect. Within the PI class, acute effects on insulin sensitivity have been observed with ritonavir and indininavir.<sup><xref ref-type="bibr" rid="bibr56-0884533611431985">56</xref></sup> Newer PIs such as atazanavir and darunavir have produced very few changes in insulin sensitivity and are recommended as preferred PIs for treatment initiation.<sup><xref ref-type="bibr" rid="bibr48-0884533611431985">48</xref>,<xref ref-type="bibr" rid="bibr57-0884533611431985">57</xref></sup></p>
<p>The HIV treatment guidelines recommend monitoring for insulin resistance by checking fasting glucose levels at baseline and every 6 months thereafter on HAART therapy.<sup><xref ref-type="bibr" rid="bibr7-0884533611431985">7</xref></sup> When glucose abnormalities on HAART are identified, the given regimen should be evaluated for the propensity of individual agents to contribute to the disorder. Substitutions of thymidine NRTIs such as stavudine have resulted in little to no glycemic improvement, but it seems an appropriate action to take to prevent worsening insulin resistance.<sup><xref ref-type="bibr" rid="bibr58-0884533611431985">58</xref>,<xref ref-type="bibr" rid="bibr59-0884533611431985">59</xref></sup> In the PI class, very few studies have evaluated PI substitutions on insulin sensitivity. Changing to ritonavir-boosted or unboosted atazanavir resulted in significant changes in 2 studies.<sup><xref ref-type="bibr" rid="bibr60-0884533611431985">60</xref>,<xref ref-type="bibr" rid="bibr61-0884533611431985">61</xref></sup> Treating insulin resistance with metformin has been studied in HIV patients with improvements in insulin sensitivity.<sup><xref ref-type="bibr" rid="bibr62-0884533611431985">62</xref></sup> Unfortunately, its use was also associated with reductions in subcutaneous adipose tissue.<sup><xref ref-type="bibr" rid="bibr63-0884533611431985">63</xref></sup> Peroxisome proliferator-activated receptor γ (PPARγ) agonists such as rosiglitazone and pioglitazone have been studied as insulin-sensitizing agents in HIV-infected patients with insulin resistance. Results were inconsistent, with some studies observing benefit and others no improvement.<sup><xref ref-type="bibr" rid="bibr64-0884533611431985">64</xref>-<xref ref-type="bibr" rid="bibr67-0884533611431985">67</xref></sup> Because of insufficient evidence to support metformin or thiazolidinediones for use in insulin resistance, these therapies are not recommended for use in HIV-infected patients without diabetes.<sup><xref ref-type="bibr" rid="bibr68-0884533611431985">68</xref></sup></p>
</sec>
<sec id="section13-0884533611431985">
<title>Lipodystrophy</title>
<p>Changes in body fat redistribution have developed in HIV-infected patients, including both lipohypertrophy and lipoatrophy. These morphologic changes became most notable and first published in the medical literature following the advent of the HAART era. Characteristic lipohypertrophy changes include central fat accumulation in the abdominal area and waist circumference, increased adipose tissue in the neck and dorsocervical area (“buffalo hump”), and breast enlargement. This may be accompanied by lipoatrophy, loss of subcutaneous adipose tissue in the cheek and temporal areas, buttocks, and peripherally (arms and legs) with prominent superficial veins in the extremities.<sup><xref ref-type="bibr" rid="bibr26-0884533611431985">26</xref></sup> The prevalence of body fat distribution abnormalities in HIV-infected patients has been estimated to range from 40%–50%.<sup><xref ref-type="bibr" rid="bibr69-0884533611431985">69</xref></sup> Both lipodystrophy and lipoatrophy are progressive changes typically observed after several years of cumulative exposure to antiretroviral therapy.</p>
<p>The underlying mechanisms for the development of lipodystrophy in HIV-infected patients are not well understood but appear to be multifactorial. Because body fat redistribution has been observed in treatment-naive patients, HIV and other host factors appear to have a role in the pathogenesis. With increased prevalence of lipodystrophy with continued use of antiretroviral therapy, it was clear that treatment had a direct role in the development of fat redistribution.<sup><xref ref-type="bibr" rid="bibr32-0884533611431985">32</xref></sup> Research indicates that there are separate mechanisms for lipodystrophy between the NRTIs and PIs. Thymidine analogue NRTIs such as stavudine, didanosine, and zidovudine can contribute to mitochondrial dysfunction and toxicity by inhibiting mitochondrial DNA polymerase-γ and interfering with respiratory chain complexes.<sup><xref ref-type="bibr" rid="bibr26-0884533611431985">26</xref></sup> These mitochondrial effects are believed to influence the peripheral subcutaneous fat wasting observed with NRTI use.<sup><xref ref-type="bibr" rid="bibr45-0884533611431985">45</xref></sup> Protease inhibitors affect adipose tissue differentiation through dysregulation of fatty acid metabolism in the adipocyte.<sup><xref ref-type="bibr" rid="bibr70-0884533611431985">70</xref></sup> Fatty acid levels increase in circulation and are taken up into visceral adipose tissue, resulting in lipohypertrophy. Several hormones have been associated with HIV fat redistribution. Adiponectin deficiency and elevations of leptin have been correlated with lipohypertrophy.<sup><xref ref-type="bibr" rid="bibr71-0884533611431985">71</xref>,<xref ref-type="bibr" rid="bibr72-0884533611431985">72</xref></sup> Growth hormone levels are reduced approximately 50% in patients with HIV lipodystrophy.<sup><xref ref-type="bibr" rid="bibr73-0884533611431985">73</xref></sup></p>
<p>Clinical concerns associated with HIV lipodystrophy include metabolic complications such as dyslipidemia and insulin resistance that generally accompany the physical changes. However, the psychological stress associated with a disfigured self-image that at times leads to nonadherence to antiretroviral therapy cannot be minimized. The management of HIV fat redistribution has been researched for more than a decade. Switching antiretroviral therapy has been investigated for the management of both lipoatrophy and lipohypertrophy.</p>
<p>Lipoatrophy studies have demonstrated improvement in limb fat when thymidine analogues (zidovudine, stavudine, didanosine) were replaced with NRTI agents such as abacavir, tenofovir, lamivudine, or emtricitabine.<sup><xref ref-type="bibr" rid="bibr59-0884533611431985">59</xref>,<xref ref-type="bibr" rid="bibr74-0884533611431985">74</xref></sup> As a result, these are the recommended agents to comprise the NRTI backbone for initial HAART therapy. Another approach to correcting lipoatrophy has been to restore subcutaneous volume by targeting collagen production in the facial tissue. Facial injections with poly-L-lactic acid have resulted in correction of HIV lipoatrophy with good patient satisfaction and continued effects up to a year following the last treatment.<sup><xref ref-type="bibr" rid="bibr75-0884533611431985">75</xref></sup></p>
<p>Lipohypertrophy has not been clearly associated with only certain PIs. Furthermore, substituting PIs to reduce adipose tissue has not yielded consistent results. As a result, this strategy is not recommended to manage fat lipohypertrophy.<sup><xref ref-type="bibr" rid="bibr76-0884533611431985">76</xref></sup> The first treatment approved for HIV lipohypertrophy was approved in 2010. Tesamorelin, a growth hormone–releasing hormone analogue, stimulates the synthesis and release of endogenous growth hormone. These hormonal improvements in clinical trials have corresponded with a 15%–18% reduction in visceral fat with reaccumulation upon discontinuation.<sup><xref ref-type="bibr" rid="bibr77-0884533611431985">77</xref>,<xref ref-type="bibr" rid="bibr78-0884533611431985">78</xref></sup> Surgical procedures with liposuction in the dorsocervical areas may be performed when pain arises from the fat accumulation.</p>
</sec>
</sec>
<sec id="section14-0884533611431985">
<title>Bone Health</title>
<sec id="section15-0884533611431985">
<title>Bone Mineral Density</title>
<p>One of the contemporary concerns is an increasing prevalence of osteopenia and osteoporosis in the HIV-infected population. In addition, there is great interest in the impact of antiretroviral therapy on bone density. Prior to the HAART era, there was evidence of alterations in bone metabolism in HIV-infected patients characterized by reduced bone formation and turnover with the greatest incidence in those with advanced disease.<sup><xref ref-type="bibr" rid="bibr79-0884533611431985">79</xref></sup> Once HAART became mainstream, retrospective studies found that decreased bone mineral density (BMD) was observed in both treatment-naive as well as treatment-experienced patients.<sup><xref ref-type="bibr" rid="bibr80-0884533611431985">80</xref></sup> In a meta-analysis of bone health in patients with HIV infection, there was a 67% incidence of reduced BMD.<sup><xref ref-type="bibr" rid="bibr81-0884533611431985">81</xref></sup> Furthermore, when HIV-infected patients were compared with uninfected controls, there was a 6-fold higher rate of low BMD and 3-fold higher rate of osteoporosis. Current research indicates that BMD is decreased 2%–6% within the first 2 years of initiating antiretroviral therapy regardless of the regimen.<sup><xref ref-type="bibr" rid="bibr82-0884533611431985">82</xref>,<xref ref-type="bibr" rid="bibr83-0884533611431985">83</xref></sup> Fracture rates also are much higher in HIV-infected patients compared with non-HIV-infected patients.<sup><xref ref-type="bibr" rid="bibr84-0884533611431985">84</xref></sup></p>
<p>The pathogenesis of reduction in BMD in patients with HIV infection appears to be multifactorial. HIV infection and antiretroviral therapy can affect BMD as well as typical osteoporosis risk factors such as low weight/BMI, smoking, steroid use, vitamin D deficiency, poor nutrition, and secondary causes such as menopause and hypogonadism. Uncontrolled viral replication and associated inflammatory response with cytokines likely contribute to decreases in bone formation. In a study of BMD in patients receiving their first HAART regimen, those patients receiving PI regimens had the greatest prevalence of low BMD.<sup><xref ref-type="bibr" rid="bibr83-0884533611431985">83</xref></sup> However, other research has not confirmed this finding.<sup><xref ref-type="bibr" rid="bibr82-0884533611431985">82</xref>,<xref ref-type="bibr" rid="bibr85-0884533611431985">85</xref></sup> Prospective research with the NRTI tenofovir has revealed early markers of bone turnover at 12 weeks, which correlated with BMD results at week 48 of the study.<sup><xref ref-type="bibr" rid="bibr86-0884533611431985">86</xref></sup> Patients taking tenofovir had a 10%–13% rate of BMD &gt;6% compared with those taking abacavir (3%–5%). Mechanisms for drug-induced bone loss are not fully elucidated but likely are variable. It is thought that tenofovir may influence bone remodeling by renal mechanisms with resultant loss of phosphorus.<sup><xref ref-type="bibr" rid="bibr87-0884533611431985">87</xref></sup> PIs may have direct effects on the bone as well as contribute to vitamin D deficiency.<sup><xref ref-type="bibr" rid="bibr88-0884533611431985">88</xref></sup> Low BMD associated with NNRTI use such as efavirenz is also believed to result from impaired vitamin D metabolism.<sup><xref ref-type="bibr" rid="bibr89-0884533611431985">89</xref></sup></p>
</sec>
<sec id="section16-0884533611431985">
<title>Vitamin D Deficiency</title>
<p>Vitamin D deficiency may contribute to the development of osteoporosis or bone fractures. Several studies have researched the prevalence and severity of vitamin D deficiency in the HIV-infected population. The prevalence has ranged from 29%–91% in these patients with severe (&lt;10 µg/L) vitamin D deficiency ranging from 10%–35%.<sup><xref ref-type="bibr" rid="bibr90-0884533611431985">90</xref>-<xref ref-type="bibr" rid="bibr92-0884533611431985">92</xref></sup></p>
<p>The development of vitamin D deficiency in HIV-infected individuals is believed to be multifactorial. Poor nutrition, insufficient vitamin D intake, and low sunlight exposure likely play a role in these patients. However, HIV-specific mechanisms that include proinflammatory cytokines (TNF-α) in HIV infection can inhibit renal hydroxylation of 25-hydroxycholecalciferol.<sup><xref ref-type="bibr" rid="bibr93-0884533611431985">93</xref></sup> In addition, in advanced HIV disease, 25(OH) vitamin D can be depleted secondary to increased consumption by T lymphocytes for maturation and proliferation.<sup><xref ref-type="bibr" rid="bibr94-0884533611431985">94</xref></sup> Last, research shows that antiretroviral therapy has direct effects on vitamin D production and homeostasis. PIs lower vitamin D levels by inhibiting renal hydroxylation of 25(OH) vitamin D and impairing the bioactivation of 1,25 (OH) dihydroxyvitamin D.<sup><xref ref-type="bibr" rid="bibr95-0884533611431985">95</xref></sup> In contrast, the NNRTIs such as efavirenz appear to induce the metabolism of 25(OH)D3 or 1,25(OH)2D3.<sup><xref ref-type="bibr" rid="bibr90-0884533611431985">90</xref></sup> In 1 study, patients treated with efavirenz were at a 2-fold higher risk for severe vitamin D deficiency (&lt;10 µg/L).<sup><xref ref-type="bibr" rid="bibr91-0884533611431985">91</xref></sup></p>
<p>In general, patients should be encouraged to focus on nutrition intake of calcium and vitamin D, make efforts to incorporate regular weight-bearing exercise, attempt smoking cessation, and minimize alcohol consumption. Current recommendations suggest replacement for vitamin D deficiency with ergocalciferol (D2) 50,000 IU weekly for 8–12 weeks followed by 1500–2000 IU/d or 50,000 IU every other week to achieve and maintain a level &gt;32 ng/mL, with some recommending a target range of 40–50 ng/mL.<sup><xref ref-type="bibr" rid="bibr96-0884533611431985">96</xref></sup> It is recommended to replace vitamin D levels prior to initiation of bisphosphonate therapy for those with low BMD for optimal bisphosphonate efficacy.<sup><xref ref-type="bibr" rid="bibr97-0884533611431985">97</xref></sup> Treatment of osteoporosis is recommended for those patients who have had a bone fracture or are postmenopausal women as well as men ≥50 years of age who have a T score of −2.5 of the lumbar spine, total hip, or femoral neck.<sup><xref ref-type="bibr" rid="bibr98-0884533611431985">98</xref></sup> In those with osteopenia, the World Health Organization (WHO) Fracture Risk Assessment Tool (FRAX) should be used to calculate the 10-year risk of a fracture. Those patients with a ≥20% 10-year risk of an osteoporotic fracture or a hip fracture risk ≥3% should begin treatment.</p>
<p>Although antiretroviral therapy can contribute to bone loss, in the HIV-infected patient who develops osteoporosis, current evidence does not support that switching antiretroviral therapy will reverse these effects to baseline. Therefore, this should not be the pharmacologic approach to management. Although evidence is mounting surrounding the bone effects of tenofovir, currently evidence is lacking regarding an increased fracture risk with use of the drug. In a treatment-naive patient with low BMD at baseline, this should not preclude the use of tenofovir. However, in the patient who develops a fracture or osteoporosis on a tenofovir-containing regimen, it would be prudent to substitute tenofovir so as not to further contribute to low BMD. Lastly, in a patient who presents with urinary phosphate wasting, hypophosphatemia, or a <italic>z</italic> score less than −2.0, discontinuation of tenofovir therapy should be considered. In cases of severe hypophosphatemia, replacement of vitamin D, phosphorus, and calcium is necessary to support bone mineralization.<sup><xref ref-type="bibr" rid="bibr99-0884533611431985">99</xref></sup></p>
<p>Bisphosphonates in general are first-line therapy. Only alendronate and zoledronic acid, however, have been formally studied in an HIV-infected population. Efficacy results from these studies reflect a BMD response similar to that observed in a non-HIV-infected population.<sup><xref ref-type="bibr" rid="bibr100-0884533611431985">100</xref>,<xref ref-type="bibr" rid="bibr101-0884533611431985">101</xref></sup></p>
</sec>
<sec id="section17-0884533611431985">
<title>Conclusion</title>
<p>The prognosis of patients living with HIV infection has improved dramatically over the past 15 years with the introduction of HAART. The challenges of treating HIV infection have shifted from AIDS-related mortality improvements to drug-induced disease from HAART, including cardiovascular disease, metabolic disorders, and bone health. These health risks imposed by HAART must be vigilantly monitored and aggressively addressed to improve the overall health of those treated for HIV infection.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: The author is on the speaker bureau for ViiV Healthcare and receives financial compensation for presentations.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533611431985">
<label>1.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Tang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Kuhen</surname><given-names>KL</given-names></name>
<name name-style="western"><surname>Wong-Staal</surname><given-names>F</given-names></name>
</person-group>. <article-title>Lentivirus replication and regulation</article-title>. <source>Annu Rev Genet</source>. <year>1999</year>;<volume>33</volume>:<fpage>133</fpage>-<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr2-0884533611431985">
<label>2.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kilby</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues</article-title>. <source>Clin Infect Dis</source>. <year>2001</year>;<volume>33</volume>(<issue>6</issue>):<fpage>873</fpage>-<lpage>884</lpage>.</citation>
</ref>
<ref id="bibr3-0884533611431985">
<label>3.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hall</surname><given-names>HI</given-names></name>
<name name-style="western"><surname>Song</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Rhodes</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Estimation of HIV incidence in the United States</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>300</volume>(<issue>5</issue>):<fpage>520</fpage>-<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr4-0884533611431985">
<label>4.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hughes</surname><given-names>MD</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>VA</given-names></name>
<name name-style="western"><surname>Hirsch</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team</article-title>. <source>Ann Intern Med</source>. <year>1997</year>;<volume>126</volume>(<issue>12</issue>):<fpage>929</fpage>-<lpage>938</lpage>.</citation>
</ref>
<ref id="bibr5-0884533611431985">
<label>5.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>
<name name-style="western"><surname>May</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Chene</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>369</volume>(<issue>9327</issue>):<fpage>119</fpage>-<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr6-0884533611431985">
<label>6.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kitahata</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Gange</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Abraham</surname><given-names>AG</given-names></name>
<etal/>
</person-group>. <article-title>Effect of early versus deferred antiretroviral therapy for HIV on survival</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>18</issue>):<fpage>1815</fpage>-<lpage>1826</lpage>.</citation>
</ref>
<ref id="bibr7-0884533611431985">
<label>7.</label>
<citation citation-type="gov" xlink:type="simple">
<collab xlink:type="simple">Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents</collab>. <article-title>Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents</article-title>. <month>January</month> <day>10</day>, <year>2011</year>:<fpage>1</fpage>-<lpage>166</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf" xlink:type="simple">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</ext-link>.</comment> <access-date>Accessed April 21, 2011</access-date>.</citation>
</ref>
<ref id="bibr8-0884533611431985">
<label>8.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Marras</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Bruggeman</surname><given-names>LA</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy</article-title>. <source>Nat Med</source>. <year>2002</year>;<volume>8</volume>(<issue>5</issue>):<fpage>522</fpage>-<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr9-0884533611431985">
<label>9.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kalayjian</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Franceschini</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>SK</given-names></name>
<etal/>
</person-group>. <article-title>Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease</article-title>. <source>AIDS</source>. <year>2008</year>;<volume>22</volume>(<issue>4</issue>):<fpage>481</fpage>-<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr10-0884533611431985">
<label>10.</label>
<citation citation-type="gov" xlink:type="simple">
<collab xlink:type="simple">Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission</collab>. <article-title>Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States</article-title>. <month>May</month> <day>24</day>, <year>2010</year>:<fpage>1</fpage>-<lpage>117</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf" xlink:type="simple">http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf</ext-link>.</comment> <access-date>Accessed July 14, 2011</access-date>.</citation>
</ref>
<ref id="bibr11-0884533611431985">
<label>11.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Thio</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Seaberg</surname><given-names>EC</given-names></name>
<name name-style="western"><surname>Skolasky</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>360</volume>(<issue>9349</issue>):<fpage>1921</fpage>-<lpage>1926</lpage>.</citation>
</ref>
<ref id="bibr12-0884533611431985">
<label>12.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Cohen</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>YQ</given-names></name>
<name name-style="western"><surname>McCauley</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Prevention of HIV-1 infection with early antiretroviral therapy</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>6</issue>):<fpage>493</fpage>-<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr13-0884533611431985">
<label>13.</label>
<citation citation-type="gov" xlink:type="simple">
<collab xlink:type="simple">US Department of Health and Human Services, US Food and Drug Administration</collab>. <article-title>Antiretroviral drugs used in the treatment of HIV infection</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm" xlink:type="simple">http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm</ext-link></comment>. <access-date>Accessed September 29, 2011</access-date>.</citation>
</ref>
<ref id="bibr14-0884533611431985">
<label>14.</label>
<citation citation-type="confproc" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kim</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Wheeler</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Ziebell</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1-infected persons, US</article-title>, <year>2007</year>. <conf-name>Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections</conf-name>; <conf-date>February 16-19, 2010</conf-date>; <conf-loc>San Francisco, CA</conf-loc>. <comment>Abstract 580</comment>.</citation>
</ref>
<ref id="bibr15-0884533611431985">
<label>15.</label>
<citation citation-type="web" xlink:type="simple">
<comment>Sustiva (efavirenz) [package insert]</comment>. <publisher-loc>Princeton, NJ</publisher-loc>: <publisher-name>Bristol-Myers Squibb Company</publisher-name>. <comment><ext-link ext-link-type="uri" xlink:href="http://packageinserts.bms.com/pi/pi_sustiva.pdf" xlink:type="simple">http://packageinserts.bms.com/pi/pi_sustiva.pdf</ext-link>.</comment> <access-date>Accessed September 30, 2011</access-date>.</citation>
</ref>
<ref id="bibr16-0884533611431985">
<label>16.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lennox</surname><given-names>JL</given-names></name>
<name name-style="western"><surname>Dejesus</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Berger</surname><given-names>DS</given-names></name>
<etal/>
</person-group>. <article-title>Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96- week efficacy, durability, subgroup, safety, and metabolic analyses</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2010</year>;<volume>55</volume>(<issue>1</issue>):<fpage>39</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr17-0884533611431985">
<label>17.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Cohen</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Andrade-Villanueva</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Clotet</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>378</volume>(<issue>9787</issue>):<fpage>229</fpage>-<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr18-0884533611431985">
<label>18.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Molina</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Cahn</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Grinsztejn</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>378</volume>(<issue>9787</issue>):<fpage>238</fpage>-<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr19-0884533611431985">
<label>19.</label>
<citation citation-type="web" xlink:type="simple">
<comment>Edurant (rilpivirine) [package insert]</comment>. <publisher-loc>Raritan, NJ</publisher-loc>: <publisher-name>Tibotec Pharmaceuticals</publisher-name>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.edurant-info.com/sites/default/files/EDURANT-PI.pdf" xlink:type="simple">http://www.edurant-info.com/sites/default/files/EDURANT-PI.pdf</ext-link>.</comment> <access-date>Accessed September 28, 2011</access-date>.</citation>
</ref>
<ref id="bibr20-0884533611431985">
<label>20.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Little</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Holte</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Routy</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Antiretroviral-drug resistance among patients recently infected with HIV</article-title>. <source>N Engl J Med</source>. <year>2002</year>;<volume>347</volume>(<issue>6</issue>):<fpage>385</fpage>-<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr21-0884533611431985">
<label>21.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wheeler</surname><given-names>WH</given-names></name>
<name name-style="western"><surname>Ziebell</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Zabina</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006</article-title>. <source>AIDS</source>. <year>2010</year>;<volume>24</volume>(<issue>8</issue>):<fpage>1203</fpage>-<lpage>1212</lpage>.</citation>
</ref>
<ref id="bibr22-0884533611431985">
<label>22.</label>
<citation citation-type="web" xlink:type="simple">
<comment>Saquinavir, fosamprenavir, omeprazole, paroxetine, tipranavir</comment>. In: <article-title>Micromedex (drug interactions database) Online [AUHSOP Intranet]</article-title>. <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>Thompson Reuters Healthcare</publisher-name>. [<access-date>cited 2011 Sep 30</access-date>]. <comment>[about 5 p.]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.thomsonhc.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.ShowDrugInteractionsResults" xlink:type="simple">http://www.thomsonhc.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.ShowDrugInteractionsResults</ext-link></comment></citation>
</ref>
<ref id="bibr23-0884533611431985">
<label>23.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Carr</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Samaras</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Thorisdottir</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kauffman</surname><given-names>GR</given-names></name>
<name name-style="western"><surname>Chisholm</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>353</volume>(<issue>9170</issue>):<fpage>2093</fpage>-<lpage>2099</lpage>.</citation>
</ref>
<ref id="bibr24-0884533611431985">
<label>24.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Melzi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Carenzi</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Cossu</surname><given-names>MV</given-names></name>
<etal/>
</person-group>. <article-title>Lipid metabolism and cardiovascular risk in HIV-1 infection and HAART: present and future problems</article-title>. <source>Cholesterol</source>. <year>2010</year>;<volume>2010</volume>:<fpage>271504</fpage>.</citation>
</ref>
<ref id="bibr25-0884533611431985">
<label>25.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Racheed</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Yan</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Lau</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study</article-title>. <source>PLoS ONE</source>. <year>2008</year>;<volume>3</volume>(<issue>8</issue>):<fpage>e3003</fpage>.</citation>
</ref>
<ref id="bibr26-0884533611431985">
<label>26.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Misra</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Garg</surname><given-names>A</given-names></name>
</person-group>. <article-title>Lipodystrophy in human immunodeficiency virus-infected patients</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>(<issue>11</issue>):<fpage>4845</fpage>-<lpage>4856</lpage>.</citation>
</ref>
<ref id="bibr27-0884533611431985">
<label>27.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mooser</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Carr</surname><given-names>A</given-names></name>
</person-group>. <article-title>Antiretroviral therapy-associated hyperlipidemia in HIV disease</article-title>. <source>Curr Opin Lipidol</source>. <year>2001</year>;<volume>12</volume>(<issue>3</issue>):<fpage>313</fpage>-<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr28-0884533611431985">
<label>28.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lenhard</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Croom</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>Weiel</surname><given-names>JE</given-names></name>
<etal/>
</person-group>. <article-title>HIV protease inhibitors stimulate hepatic triglyceride synthesis</article-title>. <source>Arteriolscler Thromb Vasc Biol</source>. <year>2000</year>;<volume>20</volume>(<issue>12</issue>):<fpage>2625</fpage>-<lpage>2629</lpage>.</citation>
</ref>
<ref id="bibr29-0884533611431985">
<label>29.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Eugenin</surname><given-names>EA</given-names></name>
<name name-style="western"><surname>Morgello</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Klotman</surname><given-names>ME</given-names></name>
<etal/>
</person-group>. <article-title>Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease</article-title>. <source>Am J Pathol</source>. <year>2008</year>;<volume>172</volume>(<issue>4</issue>):<fpage>1100</fpage>-<lpage>1111</lpage>.</citation>
</ref>
<ref id="bibr30-0884533611431985">
<label>30.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Torriani</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Kamarow</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Parker</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. <article-title>Endothelial function in human immunodeficiency virus–infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>(<issue>7</issue>):<fpage>569</fpage>-<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr31-0884533611431985">
<label>31.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Grunfeld</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Pang</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Doerrler</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1992</year>;<volume>74</volume>:<fpage>1045</fpage>-<lpage>1052</lpage>.</citation>
</ref>
<ref id="bibr32-0884533611431985">
<label>32.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Carr</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Samaras</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Burton</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors</article-title>. <source>AIDS</source>. <year>1998</year>;<volume>12</volume>:<fpage>F51</fpage>-<lpage>F58</lpage>.</citation>
</ref>
<ref id="bibr33-0884533611431985">
<label>33.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Periard</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Telente</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sudre</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>(<issue>7</issue>):<fpage>700</fpage>-<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr34-0884533611431985">
<label>34.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Van der Valk</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kastelin</surname><given-names>JJP</given-names></name>
<name name-style="western"><surname>Murphy</surname><given-names>RL</given-names></name>
<etal/>
</person-group>. <article-title>Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile</article-title>. <source>AIDS</source>. <year>2001</year>;<volume>15</volume>:<fpage>2407</fpage>-<lpage>2414</lpage>.</citation>
</ref>
<ref id="bibr35-0884533611431985">
<label>35.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Negredo</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Ribalta</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Ferre</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients</article-title>. <source>AIDS</source>. <year>2004</year>;<volume>18</volume>(<issue>5</issue>):<fpage>819</fpage>-<lpage>821</lpage>.</citation>
</ref>
<ref id="bibr36-0884533611431985">
<label>36.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Friis-Moller</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Sabin</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Weber</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Combination antiretroviral therapy and the risk of myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>349</volume>(<issue>21</issue>):<fpage>1993</fpage>-<lpage>2003</lpage>.</citation>
</ref>
<ref id="bibr37-0884533611431985">
<label>37.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Triant</surname><given-names>VA</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Hadigan</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Grinspoon</surname><given-names>SK</given-names></name>
</person-group>. <article-title>Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>(<issue>7</issue>):<fpage>2506</fpage>-<lpage>2512</lpage>.</citation>
</ref>
<ref id="bibr38-0884533611431985">
<label>38.</label>
<citation citation-type="journal" xlink:type="simple">
<collab xlink:type="simple">Strategies for Management of Antiretroviral Therapy (SMART) Study Group</collab>
<person-group person-group-type="author">
<name name-style="western"><surname>El-Sadr</surname><given-names>WM</given-names></name>
<name name-style="western"><surname>Lundgren</surname><given-names>JD</given-names></name>
<etal/>
</person-group>. <article-title>CD4+ count-guided interruption of antiretroviral treatment</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>(<issue>22</issue>):<fpage>2283</fpage>-<lpage>2296</lpage>.</citation>
</ref>
<ref id="bibr39-0884533611431985">
<label>39.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Calmy</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Gayet-Ageron</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Montecucco</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial</article-title>. <source>AIDS</source>. <year>2009</year>;<volume>23</volume>(<issue>8</issue>):<fpage>929</fpage>-<lpage>939</lpage>.</citation>
</ref>
<ref id="bibr40-0884533611431985">
<label>40.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dube</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Stein</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Aberg</surname><given-names>JA</given-names></name><etal/>
</person-group>. <article-title>Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)–infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group</article-title>. <source>Clin Infect Dis</source>. <year>2003</year>;<volume>37</volume>(<issue>5</issue>):<fpage>613</fpage>-<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr41-0884533611431985">
<label>41.</label>
<citation citation-type="journal" xlink:type="simple">
<collab xlink:type="simple">Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults</collab>. <article-title>Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol (Adult Treatment Panel III)</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>285</volume>(<issue>19</issue>):<fpage>2486</fpage>-<lpage>2497</lpage>.</citation>
</ref>
<ref id="bibr42-0884533611431985">
<label>42.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aberg</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Zackin</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Brobst</surname><given-names>SW</given-names></name><etal/>
</person-group>. <article-title>A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2005</year>;<volume>21</volume>(<issue>9</issue>):<fpage>757</fpage>-<lpage>767</lpage>.</citation>
</ref>
<ref id="bibr43-0884533611431985">
<label>43.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Balasubramanyam</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Coraza</surname><given-names>I</given-names></name>
<name name-style="western"><surname>O’Brian Smith</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “Heart Positive,” a randomized, controlled trial</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>(<issue>7</issue>):<fpage>2236</fpage>-<lpage>2247</lpage>.</citation>
</ref>
<ref id="bibr44-0884533611431985">
<label>44.</label>
<citation citation-type="gov" xlink:type="simple">
<collab xlink:type="simple">US Department of Health and Human Services</collab>. <article-title>NIH stops clinical trial on combination cholesterol treatment [press release]</article-title>. <source>NIH News</source>. <month>May</month> <day>26</day>, <year>2011</year>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.nih.gov/news/health/may2011/nhlbi-26.htm" xlink:type="simple">http://www.nih.gov/news/health/may2011/nhlbi-26.htm</ext-link>.</comment> <access-date>Accessed September 20, 2011</access-date>.</citation>
</ref>
<ref id="bibr45-0884533611431985">
<label>45.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Negredo</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Molto</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Puig</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidemia in HIV-infected patients with poor response to statins</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>:<fpage>2159</fpage>-<lpage>2164</lpage>.</citation>
</ref>
<ref id="bibr46-0884533611431985">
<label>46.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dube</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Disorders of glucose metabolism in patients infected with human immunodeficiency virus</article-title>. <source>Clin Infect Dis</source>. <year>2000</year>;<volume>31</volume>(<issue>6</issue>):<fpage>1467</fpage>-<lpage>1475</lpage>.</citation>
</ref>
<ref id="bibr47-0884533611431985">
<label>47.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="editor">
<name name-style="western"><surname>Dube</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Edmonson-Melancon</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Qian</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients</article-title>. <source>J Acquir Immunodeficiency Syndr</source>. <year>2001</year>;<volume>27</volume>(<issue>2</issue>):<fpage>130</fpage>-<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr48-0884533611431985">
<label>48.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yan</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Hruz</surname><given-names>PW</given-names></name>
</person-group>. <article-title>Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal</article-title>. <source>J Acquir Immunodeficiency Syndr</source>. <year>2005</year>;<volume>40</volume>(<issue>4</issue>):<fpage>398</fpage>-<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr49-0884533611431985">
<label>49.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Palacios</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Merchante</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Macias</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Incidence of and risk factors for insulin resistance in treatment-naïve HIV-infected patients 48 weeks after starting highly active antiretroviral therapy</article-title>. <source>Antivir Ther</source>. <year>2006</year>;<volume>11</volume>(<issue>4</issue>):<fpage>529</fpage>-<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr50-0884533611431985">
<label>50.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Brown</surname><given-names>TT</given-names></name>
<name name-style="western"><surname>Cole</surname><given-names>SR</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study</article-title>. <source>Arch Intern Med</source>. <year>2005</year>;<volume>165</volume>(<issue>10</issue>):<fpage>1179</fpage>-<lpage>1184</lpage>.</citation>
</ref>
<ref id="bibr51-0884533611431985">
<label>51.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>De Wit</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sabin</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Weber</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs (D:A:D) study</article-title>. <source>Diabetes Care</source>. <year>2008</year>;<volume>31</volume>(<issue>6</issue>):<fpage>1224</fpage>-<lpage>1229</lpage>.</citation>
</ref>
<ref id="bibr52-0884533611431985">
<label>52.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Murata</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Hruz</surname><given-names>PW</given-names></name>
<name name-style="western"><surname>Mueckler</surname><given-names>M</given-names></name>
</person-group>. <article-title>Indinavir inhibits the glucose transporter isoform Glut-4 at physiologic concentrations</article-title>. <source>AIDS</source>. <year>2002</year>;<volume>16</volume>(<issue>6</issue>):<fpage>859</fpage>-<lpage>863</lpage>.</citation>
</ref>
<ref id="bibr53-0884533611431985">
<label>53.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mallal</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>John</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Moore</surname><given-names>CB</given-names></name>
<name name-style="western"><surname>James</surname><given-names>IR</given-names></name>
<name name-style="western"><surname>McKinnon</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection</article-title>. <source>AIDS</source>. <year>2000</year>;<volume>14</volume>(<issue>10</issue>):<fpage>1309</fpage>-<lpage>1316</lpage>.</citation>
</ref>
<ref id="bibr54-0884533611431985">
<label>54.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fleishman</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Johnsen</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Systrom</surname><given-names>DM</given-names></name><etal/>
</person-group>. <article-title>Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2007</year>;<volume>292</volume>(<issue>6</issue>):<fpage>E1666</fpage>-<lpage>E1673</lpage>.</citation>
</ref>
<ref id="bibr55-0884533611431985">
<label>55.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Brown</surname><given-names>TT</given-names></name>
</person-group>. <article-title>Approach to the human immunodeficiency virus-infected patient with lipodystrophy</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>(<issue>8</issue>):<fpage>2937</fpage>-<lpage>2945</lpage>.</citation>
</ref>
<ref id="bibr56-0884533611431985">
<label>56.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Noor</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Lo</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Mulligan</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Metabolic effects of indinavir in healthy HIV-seronegative men</article-title>. <source>AIDS</source>. <year>2001</year>;<volume>15</volume>:<fpage>F11</fpage>-<lpage>F18</lpage>.</citation>
</ref>
<ref id="bibr57-0884533611431985">
<label>57.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Tomaka</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Lefebvre</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Sekar</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers</article-title>. <source>HIV Med</source>. <year>2009</year>;<volume>10</volume>(<issue>5</issue>):<fpage>318</fpage>-<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr58-0884533611431985">
<label>58.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Martinez</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Larrousee</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Podzamczer</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction</article-title>. <source>AIDS</source>. <year>2010</year>;<volume>24</volume>(<issue>3</issue>):<fpage>F1</fpage>-<lpage>F9</lpage>.</citation>
</ref>
<ref id="bibr59-0884533611431985">
<label>59.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Martin</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Carr</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study</article-title>. <source>AIDS</source>. <year>2004</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1029</fpage>-<lpage>1036</lpage>.</citation>
</ref>
<ref id="bibr60-0884533611431985">
<label>60.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Busti</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Bedimo</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Margolis</surname><given-names>DM</given-names></name>
<name name-style="western"><surname>Hardin</surname><given-names>DS</given-names></name>
</person-group>. <article-title>Improvement in insulin sensitivity and dyslipidemia in protease-inhibitor treated adult male patients after switch to atazanavir/ritonavir</article-title>. <source>J Investig Med</source>. <year>2008</year>;<volume>56</volume>(<issue>2</issue>):<fpage>539</fpage>-<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr61-0884533611431985">
<label>61.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Guffanti</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Caumo</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Galli</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects</article-title>. <source>Eur J Endocrinol</source>. <year>2007</year>;<volume>156</volume>(<issue>4</issue>):<fpage>503</fpage>-<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr62-0884533611431985">
<label>62.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hadigan</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Rabe</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Grinspoon</surname><given-names>S</given-names></name>
</person-group>. <article-title>Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus–infected patients with fat redistribution and insulin resistance</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>(<issue>10</issue>):<fpage>4611</fpage>-<lpage>4615</lpage>.</citation>
</ref>
<ref id="bibr63-0884533611431985">
<label>63.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hadigan</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Corcoran</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Basgoz</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Metformin in the treatment of lipodystrophy syndrome: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2000</year>;<volume>284</volume>(<issue>4</issue>):<fpage>472</fpage>-<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr64-0884533611431985">
<label>64.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Gelato</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Mynarcik</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Quick</surname><given-names>JL</given-names></name><etal/>
</person-group>. <article-title>Improved insulin sensitivity and body fat redistribution in HIV-infected patients treated with rosiglitazone: a pilot study</article-title>. <source>JAIDS</source>. <year>2002</year>;<volume>31</volume>(<issue>2</issue>):<fpage>163</fpage>-<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr65-0884533611431985">
<label>65.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hadigan</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Yawetz</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial</article-title>. <source>Ann Intern Med</source>. <year>2004</year>;<volume>140</volume>(<issue>10</issue>):<fpage>786</fpage>-<lpage>794</lpage>.</citation>
</ref>
<ref id="bibr66-0884533611431985">
<label>66.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Slama</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Lanoy</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Valantin</surname><given-names>MA</given-names></name><etal/>
</person-group>. <article-title>Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)</article-title>. <source>Antivir Ther</source>. <year>2008</year>;<volume>13</volume>(<issue>1</issue>):<fpage>67</fpage>-<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr67-0884533611431985">
<label>67.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Tungsiripat</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Bejjani</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Rizk</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens</article-title>. <source>AIDS</source>. <year>2010</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1291</fpage>-<lpage>1298</lpage>.</citation>
</ref>
<ref id="bibr68-0884533611431985">
<label>68.</label>
<citation citation-type="web" xlink:type="simple">
<collab xlink:type="simple">European AIDS Clinical Society</collab>. <article-title>Guidelines on prevention and management of non-infectious co-morbidities in HIV</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.europeanaidsclinicalsociety.org/guidelinespdf/2_Non_Infectious_Co_Morbidities_in_HIV.pdf" xlink:type="simple">http://www.europeanaidsclinicalsociety.org/guidelinespdf/2_Non_Infectious_Co_Morbidities_in_HIV.pdf</ext-link>.</comment> <access-date>Accessed July 20, 2011</access-date>.</citation>
</ref>
<ref id="bibr69-0884533611431985">
<label>69.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Schamblean</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Benson</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Carr</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society–USA panel</article-title>. <source>J Acquir Immune Defic Synd</source>. <year>2002</year>;<volume>31</volume>:<fpage>257</fpage>-<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr70-0884533611431985">
<label>70.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sekhar</surname><given-names>RV</given-names></name>
<name name-style="western"><surname>Jahoor</surname><given-names>F</given-names></name>
<name name-style="western"><surname>White</surname><given-names>AC</given-names></name><etal/>
</person-group>. <article-title>Metabolic basis of HIV-lipodystrophy syndrome</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2002</year>;<volume>283</volume>(<issue>2</issue>):<fpage>E332</fpage>-<lpage>E337</lpage>.</citation>
</ref>
<ref id="bibr71-0884533611431985">
<label>71.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Addy</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Gavrila</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Tsiodras</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2003</year>;<volume>88</volume>(<issue>2</issue>):<fpage>627</fpage>-<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr72-0884533611431985">
<label>72.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Nagy</surname><given-names>GS</given-names></name>
<name name-style="western"><surname>Tsiodras</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Martin</surname><given-names>LD</given-names></name><etal/>
</person-group>. <article-title>Human immunodeficiency virus type 1–related lipoatrophy and lipohypertrophy are associated with serum concentrations of leption</article-title>. <source>Clin Infect Dis</source>. <year>2003</year>;<volume>36</volume>(<issue>6</issue>):<fpage>795</fpage>-<lpage>802</lpage>.</citation>
</ref>
<ref id="bibr73-0884533611431985">
<label>73.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rietschel</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Hadigan</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Corcoran</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Assessment of growth hormone dynamics in human immunodeficiency virus–related lipodystrophy</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2001</year>;<volume>86</volume>(<issue>2</issue>):<fpage>504</fpage>-<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr74-0884533611431985">
<label>74.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Moyle</surname><given-names>GJ</given-names></name>
<name name-style="western"><surname>Sabin</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Cartledge</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>(<issue>16</issue>):<fpage>2043</fpage>-<lpage>2050</lpage>.</citation>
</ref>
<ref id="bibr75-0884533611431985">
<label>75.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Levy</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Redbord</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Hanke</surname><given-names>CW</given-names></name>
</person-group>. <article-title>Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study</article-title>. <source>J Am Acad Dermatol</source>. <year>2008</year>;<volume>59</volume>(<issue>6</issue>):<fpage>923</fpage>-<lpage>933</lpage>.</citation>
</ref>
<ref id="bibr76-0884533611431985">
<label>76.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Leung</surname><given-names>VL</given-names></name>
<name name-style="western"><surname>Glesby</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Pathogenesis and treatment of HIV lipohypertrophy</article-title>. <source>Curr Opin Infect Dis</source>. <year>2011</year>;<volume>24</volume>(<issue>1</issue>):<fpage>43</fpage>-<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr77-0884533611431985">
<label>77.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Falutz</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Allas</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Blot</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Metabolic effects of growth hormone-releasing factor in patients with HIV</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>23</issue>):<fpage>2359</fpage>-<lpage>2370</lpage>.</citation>
</ref>
<ref id="bibr78-0884533611431985">
<label>78.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Falutz</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Potvin</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Mamputu</surname><given-names>JC</given-names></name><etal/>
</person-group>. <article-title>Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2010</year>;<volume>53</volume>(<issue>3</issue>):<fpage>311</fpage>-<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr79-0884533611431985">
<label>79.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Serrano</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Marinoso</surname><given-names>ML</given-names></name>
<name name-style="western"><surname>Soriano</surname><given-names>JC</given-names></name><etal/>
</person-group>. <article-title>Bone remodeling in human immunodeficiency virus-1-infected patients: a histomorphometric study</article-title>. <source>Bone</source>. <year>1995</year>;<volume>16</volume>:<fpage>185</fpage>-<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr80-0884533611431985">
<label>80.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Nolan</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Upton</surname><given-names>R</given-names></name>
<name name-style="western"><surname>McKinnon</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir</article-title>. <source>AIDS</source>. <year>2001</year>;<volume>15</volume>(<issue>7</issue>):<fpage>1275</fpage>-<lpage>1280</lpage>.</citation>
</ref>
<ref id="bibr81-0884533611431985">
<label>81.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Brown</surname><given-names>TT</given-names></name>
<name name-style="western"><surname>Qaqish</surname><given-names>RB</given-names></name>
</person-group>. <article-title>Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review</article-title>. <source>AIDS</source>. <year>2006</year>;<volume>20</volume>(<issue>17</issue>):<fpage>2165</fpage>-<lpage>2174</lpage>.</citation>
</ref>
<ref id="bibr82-0884533611431985">
<label>82.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Brown</surname><given-names>TT</given-names></name>
<name name-style="western"><surname>McComsey</surname><given-names>GA</given-names></name>
<name name-style="western"><surname>King</surname><given-names>MS</given-names></name><etal/>
</person-group>. <article-title>Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2009</year>;<volume>51</volume>(<issue>5</issue>):<fpage>554</fpage>-<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr83-0884533611431985">
<label>83.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Duvivier</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Kolta</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Assoumou</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Greater decrease in bone mineral density with protease inhibitor regimens compared with non-nucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naïve patients</article-title>. <source>AIDS</source>. <year>2009</year>;<volume>23</volume>(<issue>7</issue>):<fpage>817</fpage>-<lpage>824</lpage>.</citation>
</ref>
<ref id="bibr84-0884533611431985">
<label>84.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Triant</surname><given-names>VA</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>TT</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Fracture prevalence among immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>(<issue>9</issue>):<fpage>3499</fpage>-<lpage>3504</lpage>.</citation>
</ref>
<ref id="bibr85-0884533611431985">
<label>85.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fernandez-Rivera</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Garcia</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Loranzo</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Relationship between low mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients</article-title>. <source>HIV Clin Trials</source>. <year>2003</year>;<volume>4</volume>(<issue>5</issue>):<fpage>337</fpage>-<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr86-0884533611431985">
<label>86.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Stellbrink</surname><given-names>HJ</given-names></name>
<name name-style="western"><surname>Orkin</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Arribas</surname><given-names>JR</given-names></name><etal/>
</person-group>. <article-title>Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study</article-title>. <source>Clin Infect Dis</source>. <year>2010</year>;<volume>51</volume>(<issue>8</issue>):<fpage>963</fpage>-<lpage>972</lpage>.</citation>
</ref>
<ref id="bibr87-0884533611431985">
<label>87.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fux</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Rauch</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Simcock</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study</article-title>. <source>Antivir Ther</source>. <year>2008</year>;<volume>13</volume>(<issue>8</issue>):<fpage>1077</fpage>-<lpage>1082</lpage>.</citation>
</ref>
<ref id="bibr88-0884533611431985">
<label>88.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Faccio</surname><given-names>R</given-names></name>
</person-group>. <article-title>The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling</article-title>. <source>J Clin Invest</source>. <year>2004</year>;<volume>114</volume>(<issue>2</issue>):<fpage>206</fpage>-<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr89-0884533611431985">
<label>89.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Herzmann</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Arasteh</surname><given-names>K</given-names></name>
</person-group>. <article-title>Efavirenz-induced osteomalacia</article-title>. <source>AIDS</source>. <year>2009</year>;<volume>23</volume>(<issue>2</issue>):<fpage>274</fpage>-<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr90-0884533611431985">
<label>90.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Van Den Bout–Van Den Beukel</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Fievez</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Michels</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Vitamin D deficiency among HIV type-1-infected individuals in the Netherlands: effects of antiretroviral therapy</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2008</year>;<volume>24</volume>:<fpage>1375</fpage>-<lpage>1382</lpage>.</citation>
</ref>
<ref id="bibr91-0884533611431985">
<label>91.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Welz</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Childs</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Ibrahim</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase</article-title>. <source>AIDS</source>. <year>2010</year>;<volume>24</volume>(<issue>12</issue>):<fpage>1923</fpage>-<lpage>1928</lpage>.</citation>
</ref>
<ref id="bibr92-0884533611431985">
<label>92.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rodriguez</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Daniels</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Gunawardene</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Robbins</surname><given-names>GK</given-names></name>
</person-group>. <article-title>High frequency of vitamin D deficiency in ambulatory HIV-positive patients</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2009</year>;<volume>25</volume>(<issue>1</issue>):<fpage>9</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr93-0884533611431985">
<label>93.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Haug</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Aukrust</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Haug</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1998</year>;<volume>83</volume>(<issue>11</issue>):<fpage>3832</fpage>-<lpage>3838</lpage>.</citation>
</ref>
<ref id="bibr94-0884533611431985">
<label>94.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Villamor</surname><given-names>E</given-names></name>
</person-group>. <article-title>A potential role for vitamin D on HIV infection?</article-title> <source>Nutr Rev</source>. <year>2006</year>;<volume>64</volume>(<issue>5</issue>):<fpage>226</fpage>-<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr95-0884533611431985">
<label>95.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Cozzolino</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Vidal</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Arcidiacono</surname><given-names>MV</given-names></name><etal/>
</person-group>. <article-title>HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D</article-title>. <source>AIDS</source>. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>513</fpage>-<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr96-0884533611431985">
<label>96.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Holick</surname><given-names>MF</given-names></name>
</person-group>. <article-title>Vitamin D deficiency</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>3</issue>):<fpage>266</fpage>-<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr97-0884533611431985">
<label>97.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Adami</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Giannini</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Bianchi</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Vitamin D status and response to treatment in postmenopausal osteoporosis</article-title>. <source>Osteoporos Int</source>. <year>2009</year>;<volume>20</volume>(<issue>2</issue>):<fpage>239</fpage>-<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr98-0884533611431985">
<label>98.</label>
<citation citation-type="book" xlink:type="simple">
<collab xlink:type="simple">National Osteoporosis Foundation</collab>. <source>Clinician’s Guide to Prevention and Treatment of Osteoporosis</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Osteoporosis Foundation</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr99-0884533611431985">
<label>99.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>McComsey</surname><given-names>GA</given-names></name>
<name name-style="western"><surname>Tebas</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Shane</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Bone disease in HIV infection: a practice review and recommendations for HIV care providers</article-title>. <source>Clin Infect Dis</source>. <year>2010</year>;<volume>51</volume>(<issue>8</issue>):<fpage>937</fpage>-<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr100-0884533611431985">
<label>100.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>McComsey</surname><given-names>GA</given-names></name>
<name name-style="western"><surname>endall</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Tebas</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV</article-title>. <source>AIDS</source>. <year>2007</year>;<volume>21</volume>(<issue>18</issue>):<fpage>2473</fpage>-<lpage>2482</lpage>.</citation>
</ref>
<ref id="bibr101-0884533611431985">
<label>101.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bolland</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Grey</surname><given-names>AB</given-names></name>
<name name-style="western"><surname>Horne</surname><given-names>AM</given-names></name><etal/>
</person-group>. <article-title>Annual zoledronate increases bone density in highly active antiretroviral therapy–treated human immunodeficiency virus–infected men: a randomized controlled trial</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>(<issue>4</issue>):<fpage>1283</fpage>-<lpage>1288</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>